Chevron stock climbs in premarket as Venezuela shock puts its lone foothold in focus

Chevron stock climbs in premarket as Venezuela shock puts its lone foothold in focus

NEW YORK, Jan 5, 2026, 04:26 ET — Premarket

  • Chevron up about 2.3% in premarket; Exxon and ConocoPhillips also higher
  • Venezuela’s Maduro capture and Trump’s remarks revive focus on U.S. sanctions and operating licenses
  • Traders are watching for policy updates ahead of the U.S. open and Chevron’s late-January earnings

Chevron shares rose 2.3% to $155.90 in premarket trading on Monday, as investors tracked fast-moving headlines out of Venezuela and what they could mean for the U.S. oil major’s long-standing presence there. Exxon was up 1.9% and ConocoPhillips gained 3.3%, while refiner Valero added 1.5%.

The move followed the U.S. capture of Venezuelan President Nicolás Maduro over the weekend after President Donald Trump said Washington would take control of the country while keeping a U.S. embargo on Venezuelan oil in place, Reuters reported. Oil prices slipped as traders pointed to ample supply, with Brent down 0.8% at $60.26 a barrel and U.S. West Texas Intermediate down 0.9% to $56.79; OPEC+ — OPEC and allies including Russia — opted to keep output steady on Sunday. Reuters

Chevron is the only U.S. oil major still operating in Venezuela and exports about 150,000 barrels per day (bpd) — barrels produced each day — from the country to the U.S. Gulf Coast under a restricted U.S. authorization, Reuters reported. Trump scrapped a broader license in February, then granted a tighter authorization in July that allows limited operations and oil swaps, which avoid cash payments, provided no money goes to the Maduro administration; Chief Executive Mike Wirth said in December he had spoken with both the Biden and Trump administrations about maintaining a U.S. presence. “It will take tens of billions of dollars to turn that industry around,” Peter McNally, global head of sector analysts at Third Bridge, said; Chevron said it is focused on employee safety and operating in full compliance with U.S. rules. Reuters

Outside the majors, investors are also tracking signs of a scramble for Venezuelan assets if U.S. policy shifts. Ali Moshiri, a retired Chevron executive, is raising $2 billion for Venezuelan oil projects after the Maduro capture, the Financial Times reported, and said he has fielded a dozen investor calls in the past 24 hours. Reuters

For Chevron shareholders, the immediate question is whether Washington rewrites the operating rulebook. A broader license or a softer sanctions posture would likely matter more for the company than the day-to-day swing in crude, because it would change how much Venezuelan oil can move and under what terms.

The early price action suggested traders are treating Venezuela as a company-specific optionality story rather than a straight bet on higher oil. With crude lower, the stock’s pop pointed to expectations that Chevron may be better positioned than peers if U.S. policy opens doors — or at least clarifies the path — for American firms in the country.

But the Venezuela trade has sharp edges. Political uncertainty can freeze investment decisions, and any meaningful rebuilding effort takes time and capital, limiting what markets can reasonably pull forward into near-term earnings and cash flow.

On the chart, traders are also watching Chevron’s longer-term range: the stock has traded between $132.04 and $168.96 over the past 52 weeks, according to MarketWatch data. MarketWatch

Stock Market Today

  • Novartis (SWX:NOVN) Seen Undervalued Despite Strong Multi-Year Gains
    January 31, 2026, 11:19 AM EST. Novartis shares trade around $114.62 after a 0.9% pullback in the past week and a 1-year return of 24.2%, lagging peers. The pharmaceutical giant boasts 70.3% returns over three years and 80% over five years. Our Discounted Cash Flow (DCF) model, projecting future cash flows until 2030, values Novartis stock at $254.07 per share, suggesting a 54.9% undervaluation versus the current price. With free cash flow projected to rise from $18.2 billion to $21.2 billion by 2030, the company's valuation looks attractive. The price-to-earnings (P/E) ratio complements this view, linking share price to earnings growth and risk. Novartis scores 5 out of 6 on undervaluation metrics, supporting the case for potential entry or hold for investors.
AMD stock jumps in premarket as CES 2026 and fresh AI demand signals reset the trade
Previous Story

AMD stock jumps in premarket as CES 2026 and fresh AI demand signals reset the trade

Exxon Mobil stock jumps in premarket on Venezuela headlines — what to watch before the bell
Next Story

Exxon Mobil stock jumps in premarket on Venezuela headlines — what to watch before the bell

Go toTop